SMS Lifesciences Limited, also known as Haleos Labs Limited, has announced a temporary withholding of dividend payments for certain shareholders. This decision comes in the wake of incomplete Know Your Customer (KYC) details and incorrect bank account information for some investors.

Dividend Details

The company approved a dividend of 15% (₹1.50 per equity share of ₹10 each) for the financial year 2024-25 at their 19th Annual General Meeting held on September 30, 2025. The record date for this dividend was set as September 24, 2025.

Reasons for Dividend Withholding

The dividend payments have been withheld for shareholders due to:

1. Non-updation of KYC details, including:
   • PAN (Permanent Account Number)
   • Address
   • Email ID
   • Mobile number
   • Bank mandate
2. Rejection of dividend payments by banks due to incorrect bank account details

Communication to Affected Shareholders

SMS Lifesciences has taken proactive steps to address this issue:

• Individual letters were sent to affected shareholders on November 6, 2025
• Shareholders were informed that dividends will be released only upon compliance with KYC requirements as per SEBI regulations

Action Required from Shareholders

Shareholders need to take the following actions to receive their dividends:

1. For Physical Shareholders: Submit required documents to the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited

2. For Electronic Shareholders: Update details with their Depository Participant

Document Requirements for Physical Shareholders

SMS Lifesciences has emphasized that upon receipt and verification of updated details, the withheld dividends will be released to the registered bank accounts of the shareholders.

This move by SMS Lifesciences aligns with the SEBI circular dated December 31, 2024, and underscores the importance of maintaining up-to-date KYC information for smooth financial transactions in the stock market.

SMS Lifesciences , formerly known as SMS Lifesciences India Limited and now operating as Haleos Labs Limited, has announced a significant milestone in its international expansion efforts. The company's API manufacturing facility in Telangana has successfully completed an inspection by the Brazilian Health Authority (ANVISA), marking a crucial step towards entering the Brazilian pharmaceutical market.

Successful ANVISA Inspection

The inspection, conducted from September 22-26, 2025, focused on Haleos Labs' API manufacturing facility located at Sy. No. 180/2, Kazipally (V) Jinnaram MandaI, Sanga Reddy District, Telangana - 502319 (Unit -1). The successful completion of this audit reaffirms the company's compliance with international quality standards and opens up new opportunities for growth in South America.

Strategic Importance

Brazil represents the largest pharmaceutical market in South America, making this regulatory approval particularly significant for Haleos Labs. The company views this development as a gateway to expand its presence in the region and potentially increase its market share in the API manufacturing sector.

Company Transition

It's worth noting that Haleos Labs Limited is currently in the process of transitioning from its former name, SMS Lifesciences India Limited. The company is adopting the new name in compliance with applicable regulatory requirements. This rebranding effort coincides with the company's push for international expansion and regulatory approvals.

Management Commentary

Trupti Ranjan Mohanty, a company representative, stated, "This successful inspection reaffirms our company's compliance with international quality standards and paves the way for entry into Brazil, the largest pharmaceutical market in South America."

The successful ANVISA audit marks a significant achievement for Haleos Labs Limited, potentially opening doors to new business opportunities and reinforcing its position in the global pharmaceutical API manufacturing industry. As the company continues its rebranding process and expands its international footprint, investors and industry observers will likely keep a close watch on its progress in the Brazilian market and beyond.